IceCure Medical announces two publications for ProSense cryoablation system

IceCure Medical (ICCM) announced two publications reporting positive results for the ProSense cryoablation system in breast cancer stemming from the THERMAC Trial, an independent study taking place in the Netherlands which compares different methods of thermal ablation used for early-stage breast cancer. ProSense has regulatory approval for breast cancer in the European Union. The findings included the following: Overall median cosmetic outcome was good after thermal ablation, and intermediate after surgery; Most domains of BREAST-Q were scored higher after thermal ablation as compared to breast conserving surgery; 95% of patients were very satisfied or satisfied with thermal ablation; 91% would prefer thermal ablation over surgery; On BCCT core 94% of cases were rated as good or excellent after thermal ablation, compared to 80% after surgery